Tuesday, April 07, 2015 1:12:46 PM
This shows Cellceutix is moving forward with multiple indications. This is based upon completed research from the PolyMedix acquisition which has been confirmed by further research at Cellceutix. "Hands full" is nonsense, they have sufficient research staff and have made key additions.
Cellceutix added James Alexander, MD, MPH, FACP as Chief Operating Officer, and formerly of PolyMedix, Daniel Jorgensen, MD, MPH, MBA, FAAP as Chief Medical Officer. This in addition to a full research and support staff. They hardly have their "hands full" as proven by how productive they are. They took Brilacidin from acquisition to a P2b clinical trial successful completion in just over a year. A remarkable accomplishment.
"Nothing substantial to show" is more nonsense, there is the recently completed Phase 2b Clinical Trial for Brilacidin with positive top-line results. A successful clinical trial. Further detail to debut this month at a leading industry convention, ECCMID 2015. A successful clinical trial is very substantial for a clinical stage biotech.
The Prurisol trial completed successfully.
The Kevetrin trial is continuing successfully, an almost certain Phase 1 primary outcome measure success at this point, with a latter stage trial already approved and standing by to begin.
A Brilacidin-OM trial is approved, also based upon completed PolyMedix research.
Here is a link to Cellceutix trials: https://www.clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search
Cellceutix just closed a $30 million financing deal, it's third with Aspire Capital. This is substantial and gives Cellceutix funds necessary to move forward on all planned investigational drugs, both in clinical trials and in pre-clinical research.
Cellceutix has applied for up-listing with the NASDAQ.
What Cellceutix does not have is even one failed clinical trial, everything is coming up roses. There is a tremendous amount of substance shown by Cellceutix.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM